Phase III Study of Telitacicept in Patients With IgA Nephropathy
Status:
Not yet recruiting
Trial end date:
2026-09-30
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to compare Telitacicept with placebo in patients with IgA
nephropathy.
The main questions it aims to answer are:
- To evaluate the clinical efficacy of Telitacicept in patients with IgA nephropathy.
- To evaluate the safety and adverse reaction of Telitacicept in patients with IgA
nephropathy.
Participants will be subcutaneously injected with 240mg of Telitacicept once per week.
Researchers will compare placebo-controlled group to see if Telitacicept works better.
Phase:
Phase 3
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University